Minor and clinically non-significant interaction between toloxatone and amitriptyline
β Scribed by S. Vandel; G. Bertschy; M. C. Perault; M. Sandoz; S. Bouquet; R. Chakroun; S. Guibert; B. Vandel
- Publisher
- Springer
- Year
- 1993
- Tongue
- English
- Weight
- 263 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
β¦ Synopsis
The possibility of a pharmacokinetic interaction between amitriptyline and toloxatone (a new MAOI-A) has been studied in 17 depressed in-patients. Amitriptyline and its demethylated and hydroxylated metabolites in blood and urine were measured at steady state after the administration of amitriptyline with and without toloxatone in steady state. The metabolic status of patients was determined using the dextromethorphan phenotyping test. There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone. The urinary excretion and plasma levels of AMT and its metabolites were not affected by the co-therapy. Three of the patients were poor metabolisers, but this did not predict the magnitude of the drug interaction. The interaction does not justify plasma level monitoring of amitriptyline as the change in pharmacokinetics was so small.
π SIMILAR VOLUMES
The hypothesis that the cytoprotective agent sucralfate (sucrose octakis(hydrogen sulfate)-aluminum complex) interacts with !he H,-antagonist ranitidine (N[2-[[5-[(dimethylamino)methyl]futfuryl]thio]ethyl]-N'-methyl-2-nitro-l ,1 -ethenediamine) by decreasing ranitidine absorption was tested in vitro
DNA ploidy of tumor cells and the degree of infiltration of dendritic cells were determined in 93 gastric cancer tissue specimens, and the mechanisms of tumor-host interaction on the prognosis were investigated. DNA ploidy patterns were grouped into low and high ploidy, and the degree of infiltratio